{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:06:23Z","timestamp":1793286383637,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The COVID-19 pandemic poses a global threat to public health and economy. The continuously emerging SARS-CoV-2 variants present a major challenge to the development of antiviral agents and vaccines. In this study, we identified that EK1 and cholesterol-coupled derivative of EK1, EK1C4, as pan-CoV fusion inhibitors, exhibit potent antiviral activity against SARS-CoV-2 infection in both lung- and intestine-derived cell lines (Calu-3 and Caco2, respectively). They are also effective against infection of pseudotyped SARS-CoV-2 variants B.1.1.7 (Alpha) and B.1.1.248 (Gamma) as well as those with mutations in S protein, including N417T, E484K, N501Y, and D614G, which are common in South African and Brazilian variants. Crystal structure revealed that EK1 targets the HR1 domain in the SARS-CoV-2 S protein to block virus-cell fusion and provide mechanistic insights into its broad and effective antiviral activity. Nasal administration of EK1 peptides to hACE2 transgenic mice significantly reduced viral titers in lung and intestinal tissues. EK1 showed good safety profiles in various animal models, supporting further clinical development of EK1-based pan-CoV fusion inhibitors against SARS-CoV-2 and its variants.<\/jats:p>","DOI":"10.1038\/s41392-021-00712-2","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T09:02:58Z","timestamp":1627549378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation"],"prefix":"10.1038","volume":"6","author":[{"given":"Shuai","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5524-3542","authenticated-orcid":false,"given":"Qiaoshuai","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanke","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-7141","authenticated-orcid":false,"given":"Jan","family":"M\u00fcnch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7052-2360","authenticated-orcid":false,"given":"Frank","family":"Kirchhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2416-7708","authenticated-orcid":false,"given":"Youhua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8283-7135","authenticated-orcid":false,"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2255-0391","authenticated-orcid":false,"given":"Lu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"712_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"712_CR2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","volume":"5","author":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses.","year":"2020","unstructured":"Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536\u2013544 (2020).","journal-title":"Nat. Microbiol."},{"key":"712_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"712_CR4","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/gutjnl-2020-321013","volume":"69","author":"L Lin","year":"2020","unstructured":"Lin, L. et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 69, 997\u20131001 (2020).","journal-title":"Gut"},{"key":"712_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijid.2020.04.027","volume":"96","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int. J. Infect. Dis. 96, 19\u201324 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"712_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-021-03426-1","volume":"593","author":"NG Davies","year":"2021","unstructured":"Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593, 270\u2013274 (2021).","journal-title":"Nature"},{"key":"712_CR7","doi-asserted-by":"publisher","first-page":"eabg6916","DOI":"10.1126\/sciimmunol.abg6916","volume":"6","author":"M Sakharkar","year":"2021","unstructured":"Sakharkar, M. et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Sci. Immunol. 6, eabg6916 (2021).","journal-title":"Sci. Immunol."},{"key":"712_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622 (2021).","journal-title":"Nature"},{"key":"712_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","volume":"30","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 30, 343\u2013355 (2020).","journal-title":"Cell Res."},{"key":"712_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41422-020-00460-y","volume":"31","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Res. 31, 126\u2013140 (2021).","journal-title":"Cell Res."},{"key":"712_CR11","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","volume":"183","author":"TM Clausen","year":"2020","unstructured":"Clausen, T. M. et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183, 1043\u20131057 (2020).","journal-title":"Cell"},{"key":"712_CR12","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"CL Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"712_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"712_CR14","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","volume":"184","author":"D Zhou","year":"2021","unstructured":"Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348\u20132361 (2021).","journal-title":"Cell"},{"key":"712_CR15","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372\u20132383 (2021).","journal-title":"Cell"},{"key":"712_CR16","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","volume":"184","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384\u20132393 (2021).","journal-title":"Cell"},{"key":"712_CR17","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","volume":"184","author":"L Lu","year":"2021","unstructured":"Lu, L., Su, S., Yang, H. & Jiang, S. Antivirals with common targets against highly pathogenic viruses. Cell 184, 1604\u20131620 (2021).","journal-title":"Cell"},{"key":"712_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-020-0184-0","volume":"5","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct. Target Ther. 5, 92 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"712_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","volume":"17","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol. Immunol. 17, 765\u2013767 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"712_CR20","doi-asserted-by":"publisher","first-page":"eaav4580","DOI":"10.1126\/sciadv.aav4580","volume":"5","author":"S Xia","year":"2019","unstructured":"Xia, S. et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci. Adv. 5, eaav4580 (2019).","journal-title":"Sci. Adv."},{"key":"712_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s13238-020-00806-7","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang, X., Xia, S., Zhu, Y., Lu, L. & Jiang, S. Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. Protein Cell 12, 84\u201388 (2021).","journal-title":"Protein Cell"},{"key":"712_CR22","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jinf.2020.02.016","volume":"80","author":"W Yang","year":"2020","unstructured":"Yang, W. et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J. Infect. 80, 388\u2013393 (2020).","journal-title":"J. Infect."},{"key":"712_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S2468-1253(20)30126-6","volume":"5","author":"R Mao","year":"2020","unstructured":"Mao, R. et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 5, 667\u2013678 (2020).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"712_CR24","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","volume":"583","author":"L Bao","year":"2020","unstructured":"Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830\u2013833 (2020).","journal-title":"Nature"},{"key":"712_CR25","unstructured":"Tgtn(CAG-human ACE2-IRES-Luciferase). NM-TG-200002. https:\/\/www.modelorg.com."},{"key":"712_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/jat.3936","volume":"40","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Preclinical safety evaluation of ET-26 hydrochloride, a novel intravenous anesthetic agent, in beagle dogs. J. Appl. Toxicol. 40, 679\u2013690 (2020).","journal-title":"J. Appl. Toxicol."},{"key":"712_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jconrel.2006.08.004","volume":"115","author":"T Matsuyama","year":"2006","unstructured":"Matsuyama, T., Morita, T., Horikiri, Y., Yamahara, H. & Yoshino, H. Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent. J. Control Release 115, 183\u2013188 (2006).","journal-title":"J. Control Release"},{"key":"712_CR28","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.cell.2021.02.042","volume":"184","author":"Q Li","year":"2021","unstructured":"Li, Q. et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell 184, 2362\u20132371 (2021).","journal-title":"Cell"},{"key":"712_CR29","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA 324, 782\u2013793 (2020).","journal-title":"JAMA"},{"key":"712_CR30","doi-asserted-by":"crossref","unstructured":"Meng, X. & Liang, T. SARS-CoV-2 infection in the gastrointestinal tract: fecal-oral route of transmission for COVID-19? Gastroenterology 160, 1467\u20131469 (2021).","DOI":"10.1053\/j.gastro.2021.01.005"},{"key":"712_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.stemcr.2021.02.005","volume":"16","author":"SK Tiwari","year":"2021","unstructured":"Tiwari, S. K., Wang, S., Smith, D., Carlin, A. F. & Rana, T. M. Revealing tissue-specific SARS-CoV-2 infection and host responses using human stem cell-derived lung and cerebral organoids. Stem Cell Rep. 16, 437\u2013445 (2021).","journal-title":"Stem Cell Rep."},{"key":"712_CR32","doi-asserted-by":"publisher","first-page":"eabc3582","DOI":"10.1126\/sciimmunol.abc3582","volume":"5","author":"R Zang","year":"2020","unstructured":"Zang, R. et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci. Immunol. 5, eabc3582 (2020).","journal-title":"Sci. Immunol."},{"key":"712_CR33","doi-asserted-by":"publisher","first-page":"e00649","DOI":"10.1128\/JVI.00649-19","volume":"93","author":"H Limburg","year":"2019","unstructured":"Limburg, H. et al. TMPRSS2 is the major activating protease of Influenza A virus in primary human airway cells and Influenza B virus in human type II pneumocytes. J. Virol. 93, e00649\u201319 (2019).","journal-title":"J. Virol."},{"key":"712_CR34","doi-asserted-by":"publisher","first-page":"10016","DOI":"10.1128\/JVI.00239-10","volume":"84","author":"S Bertram","year":"2010","unstructured":"Bertram, S. et al. TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. J. Virol. 84, 10016\u201310025 (2010).","journal-title":"J. Virol."},{"key":"712_CR35","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","volume":"585","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature 585, 588\u2013590 (2020).","journal-title":"Nature"},{"key":"712_CR36","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1056\/NEJMra022812","volume":"348","author":"JM Kilby","year":"2003","unstructured":"Kilby, J. M. & Eron, J. J. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. 348, 2228\u20132238 (2003).","journal-title":"N. Engl. J. Med."},{"key":"712_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"W Kabsch","year":"2010","unstructured":"Kabsch, W. XDS. Acta Crystallogr D Biol. Crystallogr 66, 125\u2013132 (2010).","journal-title":"Acta Crystallogr D Biol. Crystallogr"},{"key":"712_CR38","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr"},{"key":"712_CR39","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol. Crystallogr 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr D Biol. Crystallogr"},{"key":"712_CR40","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1107\/S2059798318006551","volume":"74","author":"PV Afonine","year":"2018","unstructured":"Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. Sect. D Struct. Biol. 74, 531\u2013544 (2018).","journal-title":"Acta Crystallogr. Sect. D Struct. Biol."},{"key":"712_CR41","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","volume":"5","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal. Transduct. Target. Ther. 5, 282 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"712_CR42","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1128\/AAC.02232-13","volume":"58","author":"SY Jun","year":"2014","unstructured":"Jun, S. Y. et al. Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob. Agents Chemother. 58, 2084\u20132088 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"712_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.vascn.2015.02.002","volume":"75","author":"BD Guth","year":"2015","unstructured":"Guth, B. D. et al. The evaluation of drug-induced changes in cardiac inotropy in dogs: results from a HESI-sponsored consortium. J. Pharm. Toxicol. Methods 75, 70\u201390 (2015).","journal-title":"J. Pharm. Toxicol. Methods"},{"key":"712_CR44","doi-asserted-by":"publisher","first-page":"e12142","DOI":"10.1002\/1348-9585.12142","volume":"62","author":"N Zhao","year":"2020","unstructured":"Zhao, N. et al. Trichloroethylene and trichloroethanol induce skin sensitization with focal hepatic necrosis in guinea pigs. J. Occup. Health 62, e12142 (2020).","journal-title":"J. Occup. Health"},{"key":"712_CR45","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621\u2013681 (2006).","journal-title":"Pharmacol. Rev."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00712-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00712-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00712-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T09:34:52Z","timestamp":1669800892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-021-00712-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1038\/s41392-021-00712-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]},"assertion":[{"value":"10 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.L., S.J., S.X., and Q.W. are co-inventors in the patent application \u201cPeptide, its preparation and application\u201d submitted to the Chinese Patent Office (PCT application no. PCT\/CN2021\/071078). Other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"288"}}